The relationship between the daily dosage of the carbapenem meropenem (MEPM) and MEPM-resistant Pseudomonas aeruginosa

Shin Ichi Harashima, Hiroko Kondo, Atsuko Nabeshima, Masako Shimoda, Kouzaburo Yamaji, Takahiko Horiuchi, Nobuyuki Shimono, Hideyuki Ikematsu

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Pseudomonas aeruginosa is a pathogen which is known to be responsible for nosocomial infection. The appropriate use of antibiotics has become important for preventing the spread of drug-resistant P. aeruginosa. In Hara-doi Hospital, two carbapenem antibiotics, imipenem (IPM) and meropenem (MEPM), are used for patients aged 65 years or older at a daily dosage of 1.0 g and 0.5 g, respectively. Of P. aeruginosa samples isolated in 2003, the sensitivity to IPM was 54% and to MEPM it was 58%. In 2004, the sensitivity to IPM was 55%, i.e., not significantly different from 2003. In 2004, the daily dosage of MEPM was increased to 1.0 g/day, and the sensitivity to MEPM increased to 71%. Based on the Pharmacokinetics/Pharmacodynamics (PK/PD) theory, even though the patients were elderly, a sufficient dosage of antibiotics given over a shorter period of time was effective against MEPM-resistant P. aeruginosa in a hospital ward, and there were no side effects.

Original languageEnglish
Pages (from-to)219-222
Number of pages4
JournalJournal of Infection and Chemotherapy
Volume14
Issue number3
DOIs
Publication statusPublished - Jun 2008

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'The relationship between the daily dosage of the carbapenem meropenem (MEPM) and MEPM-resistant Pseudomonas aeruginosa'. Together they form a unique fingerprint.

Cite this